185 related articles for article (PubMed ID: 29631711)
1. The importance of quality-of-life management in patients with advanced pancreatic ductal adenocarcinoma.
Lewis AR; Pihlak R; McNamara MG
Curr Probl Cancer; 2018; 42(1):26-39. PubMed ID: 29631711
[TBL] [Abstract][Full Text] [Related]
2. Supportive care in pancreatic ductal adenocarcinoma.
Laquente B; Calsina-Berna A; Carmona-Bayonas A; Jiménez-Fonseca P; Peiró I; Carrato A
Clin Transl Oncol; 2017 Nov; 19(11):1293-1302. PubMed ID: 28612201
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial.
Neuzillet C; Vergnault M; Bonnetain F; Hammel P
Trials; 2015 Oct; 16():454. PubMed ID: 26458923
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer: Best supportive care.
Védie AL; Neuzillet C
Presse Med; 2019 Mar; 48(3 Pt 2):e175-e185. PubMed ID: 30878334
[TBL] [Abstract][Full Text] [Related]
5. Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma.
Deng Y; Tu H; Pierzynski JA; Miller ED; Gu X; Huang M; Chang DW; Ye Y; Hildebrandt MAT; Klein AP; Zhao R; Lippman SM; Wu X
Eur J Cancer; 2018 Mar; 92():20-32. PubMed ID: 29413686
[TBL] [Abstract][Full Text] [Related]
6. Islets and pancreatic ductal adenocarcinoma - An opportunity for translational research from the 'Bench to the Bedside'.
Barreto SG; Michael MZ; Keating DJ
Pancreatology; 2020 Apr; 20(3):385-390. PubMed ID: 32057682
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in patients with pancreatic ductal adenocarcinoma undergoing pancreaticoduodenectomy.
Laitinen I; Sand J; Peromaa P; Nordback I; Laukkarinen J
Pancreatology; 2017; 17(3):445-450. PubMed ID: 28274687
[TBL] [Abstract][Full Text] [Related]
8. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
9. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
[TBL] [Abstract][Full Text] [Related]
11. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of palliative treatments in unresectable pancreatic cancer.
Choi CC; Choi J; Houli N; Smith M; Usatoff V; Lipton L; Chan S
ANZ J Surg; 2021 May; 91(5):915-920. PubMed ID: 33870626
[TBL] [Abstract][Full Text] [Related]
13. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.
Cinar P; Ko AH
J Natl Compr Canc Netw; 2014 Feb; 12(2):167-72. PubMed ID: 24586078
[TBL] [Abstract][Full Text] [Related]
14. The quality of pain management in pancreatic cancer: A prospective multi-center study.
Damm M; Weniger M; Kölsch AK; Lampert C; Ceyhan GO; Beer S; Schorn S; Moir J; Michl P; Rosendahl J
Pancreatology; 2020 Oct; 20(7):1511-1518. PubMed ID: 32952041
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
[TBL] [Abstract][Full Text] [Related]
16. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma.
Hu X; Xia F; Lee J; Li F; Lu X; Zhuo X; Nie G; Ling D
Adv Sci (Weinh); 2021 Apr; 8(7):2002545. PubMed ID: 33854877
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
18. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
Borazanci E; Sckolnik S; Amini A
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
[TBL] [Abstract][Full Text] [Related]
19. Malignant ascites secondary to foamy gland adenocarcinoma of the pancreas.
Stewart CJ
Acta Cytol; 2009; 53(3):362-4. PubMed ID: 19534287
[No Abstract] [Full Text] [Related]
20. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
